[an error occurred while processing this directive] | [an error occurred while processing this directive]
Expert consensus on the treatment of recurrent nasopharyngeal carcinoma
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association, Lin Shaojun, Chen Xiaozhong, Li Jingao, Hu Chaosu
Department of Radiation Oncology,Fujian Cancer Hospital,Fuzhou 350005,China (Lin SJ); Department of Radiation Oncology,zhejian Cancer Hospital,Hangzhou 310022,China (Chen XZ); Department of Radiation Oncology,Jiangxi Cancer Hospital,Nanchang 330029,China (Li JG); Department of Radiation Oncology,Cancer Hospital,Fuda University,Shanghai 200032,China (Hu CS)
Abstract With the application of intensity-modulated radiotherapy,the locoregional control rate of nasopharyngeal carcinoma (NPC) has been significantly increased. However,there are still 10%-15% of patients suffering the recurrenceof NPC.Re-treatment of recurrent NPC is a difficult clinical problem. In addition,the options of recurrent NPC treatment are diverse and each one has its own advantages and disadvantages,which makes the treatment of recurrent NPC more confusing. Due to the lack of strong evidence of clinical trials,treatment guidelines and criteria cannot be formed and standardized. This consensus reviews the literature and clinical trials about the treatment of recurrent NPC,and further stratifies and summarizes the radiotherapy,surgical treatment,chemotherapy,and target therapy for recurrent NPC.Based on expert experiences,we draft out this article for clinically significant issues without sufficient clinical data,which aims to reach a preliminary consensusonthe best therapeutic strategy for recurrent NPC.
Corresponding Authors:
Lin Shaojun,Email llsj516@126.com
Cite this article:
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association,Lin Shaojun,Chen Xiaozhong et al. Expert consensus on the treatment of recurrent nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 16-22.
Committee of Nasopharyngeal Cancer of Chinese Anti-Cancer Association,Lin Shaojun,Chen Xiaozhong et al. Expert consensus on the treatment of recurrent nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2018, 27(1): 16-22.
[1] Jemal A,Bray F,Center MM,et al. Global cancer statistics[J].CACancer JClin,2011,61(2):69-90.DOI:10.3322/caac.20107 [2] Wei WI,Sham JST.Nasopharyngeal carcinoma[J].Lancet,2005,365(9476):2041-2054.DOI:10.1016/S0140-6736(05)66698-6 [3] Lai SZ,Li WF,Chen L,et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients?[J].Int J Radiat OncolBiolPhys,2011,80(3):661-668.DOI:10.1016/j.ijrobp.2010.03.024 [4] Leung TW,Tung SY,Sze WK,et al. Treatment results of 1070 patients with nasopharyngeal carcinoma:an analysis of survival and failure patterns[J].HeadNeck,2005,27(7):555-565.DOI:10.1002/hed.20189 [5] Lee AWM,Sze WM,Au JSK,et al. Treatment results for nasopharyngeal carcinoma in the modern era:the Hong Kong experience[J].Int JRadiat OncolBiolPhys,2005,61(4):1107-1116.DOI:10.1016/j.ijrobp.2004.07.702 [6] Lee AWM,Poon YF,Foo W,et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985:overall survival and patterns of failure[J].Int J Radiat OncolBiolPhys,1992,23(2):261-270.DOI:10.1016/0360-3016(92)90740-9 [7] Ng WT,Lee MCH,Chang ATY,et al. The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT[J].Oral Oncol,2014,50(5):506-512.DOI:10.1016/j.oraloncology.2014.01.017 [8] Zong JF,Lin SJ,Lin J,et al. Impact of intensity-modulated radiotherapy on nasopharyngeal carcinoma:validation of the 7th edition AJCC staging system[J].Oral Oncol,2015,51(3):254-259.DOI:10.1016/j.oraloncology.2014.10.012 [9] Sun XM,Su SF,Chen CY,et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma:an analysis of survival and treatment toxicities[J].RadiotherOncol,2014,110(3):398-403.DOI:10.1016/j.radonc.2013.10.020 [10] Liu WX,Tang Y,Gao L,et al. Nasopharyngeal carcinoma in children and adolescents-a single institution experience of 158 patients[J].RadiatOncol,2014,9:274.DOI:10.1186/s13014-014-0274-7 [11] Yi JL,Huang XD,Gao L,et al. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma[J].RadiatOncol,2014,9:56.DOI:10.1186/1748-717X-9-56 [12] Stoker SD,Van Diessen JNA,De Boer JP,et al. Current treatment options for local residual nasopharyngeal carcinoma[J].Curr Treat Options Oncol,2013,14(4):475-491.DOI:10.1007/s11864-013-0261-5 [13] Lu JJ,Cooper JS,Lee AWM.Nasopharyngeal carcinoma:multidisciplinary management[M].Berlin,Heidelberg:Springer,2010 [14] Li JX,Lu TX,Huang Y,et al. Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area[J].SciWorldJ,2012,2012:719754.DOI:10.1100/2012/719754 [15] Lee AWM,Foo W,Law SCK,et al. Recurrent nasopharyngeal carcinoma:the puzzles of long latency[J].Int J Radiat OncolBiolPhys,1999,44(1):149-156.DOI:10.1016/S0360-3016(98)00524-0 [16] Li JX,Huang SM,Jiang XH,et al. Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy[J].RadiatOncol,2014,9:87.DOI:10.1186/1748-717X-9-87 [17] Kong FF,Ying HM,Du CR,et al. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma[J].RadiatOncol,2014,9:60.DOI:10.1186/1748-717X-9-60 [18] 邸小青,胡新荣.鼻咽癌放疗后复发的分子机理研究进展[J].西南军医,2009,11(5):936-939.DOI:10.3969/j.issn.1672-7193.2009.05.085.Di XQ,Hu XR. Research progress on the molecular mechanism of recurrence after radiotherapy for nasopharyngeal carcinoma[J].J Mili Surg South Chin,2009,11(5):936-939.DOI:10.3969/j.issn.1672-7193.2009.05.085 [19] Hong B,Lui VWY,Hashiguchi M,et al. Targeting tumor hypoxia in nasopharyngeal carcinoma[J].Head Neck,2013,35(1):133-145.DOI:10.1002/hed.21877 [20] Nicholls J,Sham J,Ng MH,et al. In-situ carcinoma adjacent to recurrent nasopharyngeal carcinoma:evidence of a new growth?[J].PatholRes Pract,1993,189(9):1067-1070.DOI:10.1016/S0344-0338(11)80682-5 [21] Chan JKC,Bray F,McCarron P,et al. Tumours of the nasopharynx[A]//BamesL,Eveson JW,Reichart P,et al. Pathology and GeneticsofHead and Neck Tumours:World Heath Organization Classification of Turmours[M].Lyon:IARC,2005 [22] Ng SH,Wan YL,Ko SF,et al. MRI of nasopharyngeal carcinoma with emphasis on relationship to radiotherapy[J].J Magn Reson Imaging,1998,8(2):327-336.DOI:10.1002/jmri.1880080212 [23] Zhou HJ,Shen GH,Zhang WJ,et al.18F-FDG PET/CT for the diagnosis of residual or recurrent nasopharyngeal carcinoma after radiotherapy:a metaanalysis[J].JNucl Med,2016,57(3):342-347.DOI:10.2967/jnumed.115.165407 [24] Comoretto M,Balestreri L,Borsatti E,et al. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy:comparison of MR imaging and FDG PET/CT[J].Radiology,2008,249(1):203-211.DOI:10.1148/radiol.2491071753 [25] Yen RF,Yen MF,Hong RL,et al. The cost-utility analysis of 18-fluoro-2-deoxyglucose positron emission tomography in the diagnosis of recurrent nasopharyngeal carcinoma[J].AcadRadiol,2009,16(1):54-60.DOI:10.1016/j.acra.2008.06.012 [26] Tian YM,Zhao C,Guo Y,et al. Effect of total dose and fraction size on survival of patients with locally recurrent nasopharyngeal carcinoma treated with intensity-modulated radiotherapy:a phase 2,single-center,randomized controlled trial[J].Cancer,2014,120(22):3502-3509.DOI:10.1002/cncr.28934 [27] Han F,Zhao C,Huang SM,et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy[J].ClinOncol,2012,24(8):569-576.DOI:10.1016/j.clon.2011.11.010 [28] Hua YJ,Han F,Lu LX,et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy[J].Eur J Cancer,2012,48(18):3422-3428.DOI:10.1016/j.ejca.2012.06.016 [29] You R,Zou X,Hua YJ,et al. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma-A case-matched comparison[J].RadiotherOncol,2015,115(3):399-406.DOI:10.1016/j.radonc.2015.04.024 [30] Tian YM,Guan Y,Xiao WW,et al. Long-term survival and late complications in intensity-modulated radiotherapy of locally recurrent T1 to T2 nasopharyngeal carcinoma[J].HeadNeck,2016,38(2):225-231.DOI:10.1002/hed.23880 [31] Kong L,Wang L,Shen CY,et al. Salvage intensity-modulated radiation therapy (IMRT) for locally recurrent nasopharyngeal cancer after definitive IMRT:a novel scenario of the modern era[J].SciRep,2016,6:32883.DOI:10.1038/srep32883 [32] Tian YM,Huang WZ,Yuan X,et al. The challenge in treating locally recurrent T3-4 nasopharyngeal carcinoma:the survival benefit and severe late toxicities of re-irradiation with intensity-modulated radiotherapy[J].Oncotarget,2017,8(26):43450-43457.DOI:10.18632/oncotarget.15896 [33] Chan OSH,Sze HCK,Lee MCH,et al. Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma[J].Head Neck,2017,39(3):533-540.DOI:10.1002/hed.24645 [34] Lee AWM,Foo W,Law SCK,et al. Reirradiation for recurrent nasopharyngeal carcinoma:factors affecting the therapeutic ratio and ways for improvement[J].Int J Radiat OncolBiolPhys,1997,38(1):43-52.DOI:10.1016/S0360-3016(97)00244-7 [35] Wang CC.Re-irradiation of recurrent nasopharyngeal carcinoma-treatment techniques and results[J].Int J Radiat OncolBiolPhys,1987,13(7):953-956.DOI:10.1016/0360-3016(87)90030-7 [36] Spencer SA,Harris J,Wheeler RH,et al. Final report of RTOG 9610,a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck[J].HeadNeck,2008,30(3):281-288.DOI:10.1002/hed.20697 [37] Langer CJ,Harris J,Horwitz EM,et al. Phase Ⅱ study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck:results of Radiation Therapy Oncology Group Protocol 9911[J].J Clin Oncol,2007,25(30):4800-4805.DOI:10.1200/JCO.2006.07.9194 [38] Lee VHF,Kwong DLW,Leung TW,et al. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma[J].EurArchOtoRhinoLaryngol,2017,274(2):1067-1078.DOI:10.1007/s00405-016-4339-0 [39] Karam I,Huang SH,McNiven A,et al. Outcomes after reirradiation for recurrent nasopharyngeal carcinoma:North American experience[J].HeadNeck,2016,38(S1):E1102-E1109.DOI:10.1002/hed.24166 [40] Chua DTT,Wu SX,Lee V,et al. Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma:a matched-cohort analysis[J].Head Neck Oncol,2009,1:13.DOI:10.1186/1758-3284-1-13 [41] Wu SX,Chua DTT,Deng ML,et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma[J].Int J RadiatOncolBiolPhys,2007,69(3):761-769.DOI:10.1016/j.ijrobp.2007.03.037 [42] Ahn YC,Lee KC,Kim DY,et al. Fractionated stereotactic radiation therapy for extracranial head and neck tumors[J].Int J Radiat OncolBiolPhys,2000,48(2):501-505.DOI:10.1016/S0360-3016(00)00612-X [43] Orecchia R,Redda MGR,Ragona R,et al. Results of hypofractionated stereotactic re-irradiation on 13 locally recurrent nasopharyngeal carcinomas[J].RadiotherOncol,1999,53(1):23-28.DOI:10.1016/S0167-8140(99)00130-9 [44] Law SCK,Lam WK,Ng MF,et al. Reirradiation of nasopharyngeal carcinoma with intracavitary mold brachytherapy:an effective means of local salvage[J].Int J Radiat OncolBiolPhys,2002,54(4):1095-1113.DOI:10.1016/S0360-3016(02)03009-2 [45] Kwong DLW,Wei WI,Cheng ACK,et al. Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma[J].Cancer,2001,91(6):1105-1113.DOI:10.1002/1097-0142(20010315)91:6<1105::AID-CNCR1106>3.3.CO;2-Q [46] Leung TW,Tung SY,Sze WK,et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma[J].Int J Radiat OncolBiolPhysi,2000,48(5):1331-1338.DOI:10.1016/S0360-3016(00)00776-8 [47] Romesser PB,Cahlon O,Scher ED,et al. Proton beam reirradiation for recurrent head and neck cancer:multi-institutional report on feasibility and early outcomes[J].Int J Radiat OncolBiolPhys,2016,95(1):386-395.DOI:10.1016/j.ijrobp.2016.02.036 [48] Kong L,Hu JY,Guan XY,et al. Phase Ⅰ/Ⅱ trial evaluating carbon ion radiotherapy for salvaging treatment of locally recurrent nasopharyngeal carcinoma[J].J Cancer,2016,7(7):774-783.DOI:10.7150/jca.14399 [49] Fee WEJr,Moir MS,Choi EC,et al. Nasopharyngectomy for recurrent nasopharyngeal cancer:a 2-to 17-year follow-up[J].Arch OtolaryngolHead Neck Surg,2002,128(3):280-284.DOI:10.1001/archotol.128.3.280 [50] Wei WL,Lam KHL,Sham JST.New approach to the nasopharynx:the maxillary swing approach[J].HeadNeck,1991,13(3):200-207.DOI:10.1002/hed.2880130306 [51] King WWK,Ku PKM,Mok CO,et al. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma:a twelve-year experience[J].HeadNeck,2000,22(3):215-222.DOI:10.1002/(SICI)1097-0347(200005)22:3<215::AID-HED2>3.0.CO;2-B [52] Hsu MM,Hong RL,Ting LL,et al. Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site:experience with 60 cases[J].Arch OtolaryngolHead Neck Surg,2001,127(7):798-802 [53] Na′ara S,Amit M,Billan S,et al. Outcome of patients undergoing salvage surgery for recurrent nasopharyngeal carcinoma:a meta-analysis[J].Ann Surg Oncol,2014,21(9):3056-3062.DOI:10.1245%2Fs10434-014-3683-9 [54] Vlantis AC,Chan HS,Tong MCF,et al. Surgical salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma:a multivariate analysis of prognostic factors[J].Head Neck,2011,33(8):1126-1131.DOI:10.1002/hed.21585 [55] Chan YW,Chow VLY,Wei WI.Quality of life of patients after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma[J].Cancer,2012,118(15):3710-3718.DOI:10.1002/cncr.26719 [56] Chen MK,Lai JC,Chang CC,et al. Minimally invasive endoscopic nasopharyngectomy in the treatment of recurrent T1-2a nasopharyngeal carcinoma[J].Laryngoscope,2007,117(5):894-896.DOI:10.1097/MLG.0b013e3180381644 [57] Yoshizaki T,Wakisaka N,Murono S,et al. Endoscopic nasopharyngectomy for patients with recurrent nasopharyngeal carcinoma at the primary site[J].Laryngoscope,2005,115(8):1517-1519.DOI:10.1097/01.MLG.0000165383.35100.17 [58] Liu J,Yu HP,Sun XC,et al. Salvage endoscopic nasopharyngectomy for local recurrent or residual nasopharyngeal carcinoma:a 10-year experience[J].Int J Clin Oncol,2017,22(5):834-842.DOI:10.1007/s10147-017-1143-9 [59] You R,Zou X,Wang SL,et al. New surgical staging system for patients with recurrent nasopharyngeal carcinoma based on the AJCC/UICC rTNM classification system[J].Eur J Cancer,2015,51(13):1771-1779.DOI:10.1016/j.ejca.2015.05.014 [60] Chan JYW,Wei WI.Three-dimensional endoscopy for endoscopic salvage nasopharyngectomy:Preliminary report of experience[J].Laryngoscope,2017.DOI:10.1002/lary.26993 [61] Mai HQ,Mo HY,Deng JF,et al. Endoscopic microwave coagulation therapy for early recurrent T1 nasopharyngeal carcinoma[J].Eur J Cancer,2009,45(7):1107-1110.DOI:10.1016/j.ejca.2009.02.028 [62] Sham JST,Choy D.Nasopharyngeal carcinoma:treatment of neck node recurrence by radiotherapy[J].Australas Radiol,1991,35(4):370-373.DOI:10.1111/j.1440-1673.1991.tb03050.x [63] Zhang L,Zhu YX,Wang Y,et al. Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma:a 10-year experience[J].Ann Surg Oncol,2011,18(1):233-238.DOI:10.1245/s10434-010-1292-9 [64] 张纲,李彩,刘磊,等.鼻咽癌放疗后颈淋巴结残留/复发的手术治疗分析[J].肿瘤,2002,22(6):514-515.DOI:10.3781/j.issn.1000-7431.2002.06.025.Zhang G,Li C,Liu L,et al. Surgical treatment of cervical lymph node residual/recurrence after radiotherapy of nasopharyngeal carcinoma[J].Tomor,2002,22(6):514-515.DOI:10.3781/j.issn.1000-7431.2002.06.025 [65] 徐震纲,屠规益,唐平章.鼻咽癌放射治疗失败后的手术治疗[J].中华耳鼻咽喉科杂志,1998,33(2):103-105.DOI:10.3760/j.issn:1673-0860.1998.02.012.Xu ZG,Tu GY,Tang PZ. Surgical treatment after the failure of radiotherapy for nasopharyngeal carcinoma[J].Chin J Otolaryngol,1998,33(2):103-105.DOI:10.3760/j.issn:1673-0860.1998.02.012 [66] 闵华庆,张锋,张锦明.放疗后复发鼻咽癌的手术治疗[J].癌症,1989,8(5):365-367.Min HQ,Zhang F,Zhang JM.Surgical treatment of recurrent nasopharyngeal carcinoma after radiotherapy[J].Chin J Cancer,1989,8(5):365-367 [67] Lo WC,Wang CP,Ko JY,et al. Salvage treatment for isolated regional failure of nasopharyngeal carcinoma after primary radiotherapy[J].Ann Surg Oncol,2012,19(3):1001-1018.DOI:10.1245/s10434-011-2018-3 [68] Zhang L,Huang Y,Hong SD,et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma:a multicentre,randomised,open-label,phase 3 trial[J].Lancet,2016,388(10054):1883-1892.DOI:10.1016/S0140-6736(16)31388-5 [69] Guan Y,Liu S,Wang HY,et al. Long-term outcomes of a phase Ⅱ randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J].Chin J Cancer,2016,35:20.DOI:10.1186/s40880-016-0081-7 [70] Chan ATC,Hsu MM,Goh BC,et al. Multicenter,phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma[J].J Clin Oncol,2005,23(15):3568-3576.DOI:10.1200/JCO.2005.02.147 [71] Hsu C,Lee SH,Ejadi S,et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma:results of the KEYNOTE-028 study[J].J Clin Oncol,2017.DOI:10.1200/JCO.2017.73.3675
2018, Vol. 27 
